Abstracts tagged "myositis and regulatory cells"

Abstract Number: 2081 • 2013 ACR/ARHP Annual Meeting
Role Of Muscle Persistent CD28null T Cells In Glucocorticoid Therapy Resistance In Myositis Patients
Jayesh Pandya¹, Ingela M. Loell², Mohammad Shahadat Hossain², Mei Zong², Sukanya Raghavan², Ingrid E. Lundberg³ and Vivianne Malmström², ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are characterized by infiltration of T cells and macrophages in skeletal muscle tissue. Conventional immunosuppressive treatment has limited effects…
Abstract Number: 1672 • 2012 ACR/ARHP Annual Meeting
Myosin Skews Effector Immune Cells of Scurfy Mice to Target Muscles in an Adoptive Transfer Model of Myositis
Nicholas Young¹, Rahul Sharma², Alexandra Friedman³, Benjamin Kaffenberger¹ and Wael N. Jarjour⁴, ¹Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, ²Medicine, University of Virginia Health System, Charlottesville, VA, ³Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Myositis is associated with an inflammatory process that results in pronounced muscle weakness and is observed in some regulatory T cell (Treg) deficient mouse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].